Prevalence and prognosis of multimorbidity in heart failure with mildly reduced ejection fraction.

IF 3.4 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

Clinical Research in Cardiology Pub Date : 2026-09-01 Epub Date: 2026-01-19 DOI:10.1007/s00392-025-02840-z

Marielen Reinhardt, Michael Behnes, Mohammad Abumayyaleh, Thomas Bertsch, Michelle Goertz, Noah Abel, Alexander Schmitt, Felix Lau, Jonas Dudda, Kathrin Weidner, Ibrahim Akin, Tobias Schupp

{"title":"Prevalence and prognosis of multimorbidity in heart failure with mildly reduced ejection fraction.","authors":"Marielen Reinhardt, Michael Behnes, Mohammad Abumayyaleh, Thomas Bertsch, Michelle Goertz, Noah Abel, Alexander Schmitt, Felix Lau, Jonas Dudda, Kathrin Weidner, Ibrahim Akin, Tobias Schupp","doi":"10.1007/s00392-025-02840-z","DOIUrl":null,"url":null,"abstract":"Background and objective: Related to ongoing demographic, the number of patients with cardiac and non-cardiac comorbidities increases. Heart failure with mildly reduced ejection fraction (HFmrEF) represents a heterogeneous population with diverse clinical profiles. The study investigates the prevalence and prognostic impact of multimorbidity in patients hospitalized with HFmrEF.Methods: Consecutive patients with HFmrEF were retrospectively included at one institution from 2016 to 2022 and divided into four groups based on the number of concomitant comorbidities taking into account 12 comorbidities (i.e., 0-1, 2-3, 4-5, ≥ 6 comorbidities). The prognostic impact of the number of comorbidities was investigated with regard to the primary endpoint all-cause mortality at 30 months.Results: From 2,184 patients hospitalized with HFmrEF, 37% presented with 4-5 comorbidities, 17% with ≥ 6 comorbidities. Compared to patients with 4-5, 2-3, 0-1 comorbidities, patients with ≥ 6 comorbidities were more frequently discharged with beta-blockers (83.6% vs. 78.7% vs. 77.6% vs. 64.7%; p = 0.001) and mineralocorticoid receptor antagonists (MRA) (17.2% vs. 15.7% vs. 12.8% vs. 7.9%; p = 0.004). The risk of all-cause mortality at 30 months was higher in patients with ≥ 6 comorbidities compared to patients with less comorbidities (i.e., 4-5, 2-3, 0-1) (59.5% vs. 38.6% vs. 17.0% vs. 7.9%, p = 0.001). Both cardiovascular (HR = 1.106; 95% CI 1.030 - 1.188; p = 0.006) and non-cardiovascular (HR = 1.564; 95% CI 1.470 - 1.664; p = 0.001) comorbidities predicted the risk of long-term all-cause mortality.Conclusion: In patients hospitalized with HFmrEF, more than 50% had at least 4 comorbidities. Both cardiovascular and non-cardiovascular comorbidities predicted the risk of long-term all-cause mortality in HFmrEF.","PeriodicalId":10474,"journal":{"name":"Clinical Research in Cardiology","volume":" ","pages":"1615-1628"},"PeriodicalIF":3.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13457439/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Research in Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00392-025-02840-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Background and objective: Related to ongoing demographic, the number of patients with cardiac and non-cardiac comorbidities increases. Heart failure with mildly reduced ejection fraction (HFmrEF) represents a heterogeneous population with diverse clinical profiles. The study investigates the prevalence and prognostic impact of multimorbidity in patients hospitalized with HFmrEF.

Methods: Consecutive patients with HFmrEF were retrospectively included at one institution from 2016 to 2022 and divided into four groups based on the number of concomitant comorbidities taking into account 12 comorbidities (i.e., 0-1, 2-3, 4-5, ≥ 6 comorbidities). The prognostic impact of the number of comorbidities was investigated with regard to the primary endpoint all-cause mortality at 30 months.

Results: From 2,184 patients hospitalized with HFmrEF, 37% presented with 4-5 comorbidities, 17% with ≥ 6 comorbidities. Compared to patients with 4-5, 2-3, 0-1 comorbidities, patients with ≥ 6 comorbidities were more frequently discharged with beta-blockers (83.6% vs. 78.7% vs. 77.6% vs. 64.7%; p = 0.001) and mineralocorticoid receptor antagonists (MRA) (17.2% vs. 15.7% vs. 12.8% vs. 7.9%; p = 0.004). The risk of all-cause mortality at 30 months was higher in patients with ≥ 6 comorbidities compared to patients with less comorbidities (i.e., 4-5, 2-3, 0-1) (59.5% vs. 38.6% vs. 17.0% vs. 7.9%, p = 0.001). Both cardiovascular (HR = 1.106; 95% CI 1.030 - 1.188; p = 0.006) and non-cardiovascular (HR = 1.564; 95% CI 1.470 - 1.664; p = 0.001) comorbidities predicted the risk of long-term all-cause mortality.

Conclusion: In patients hospitalized with HFmrEF, more than 50% had at least 4 comorbidities. Both cardiovascular and non-cardiovascular comorbidities predicted the risk of long-term all-cause mortality in HFmrEF.

查看原文本刊更多论文

心力衰竭伴轻度射血分数降低的多病患病率及预后。

背景和目的：与持续的人口统计学相关，心脏和非心脏合并症患者的数量增加。心力衰竭伴轻度射血分数降低（HFmrEF）代表了具有不同临床特征的异质人群。本研究调查了HFmrEF住院患者多病的患病率和预后影响。方法：回顾性纳入2016年至2022年1家医院连续HFmrEF患者，并考虑12种合并症（即0-1、2-3、4-5、≥6种合并症），根据合并症数量分为4组。在30个月的主要终点全因死亡率方面，研究了合并症数量对预后的影响。结果：在2184例HFmrEF住院患者中，37%出现4-5个合并症，17%出现≥6个合并症。与4-5、2-3、0-1合并症的患者相比，合并症≥6的患者更常使用β受体阻滞剂（83.6% vs. 78.7% vs. 77.6% vs. 64.7%; p = 0.001）和矿皮质激素受体拮抗剂（17.2% vs. 15.7% vs. 12.8% vs. 7.9%; p = 0.004）出院。与合并症较少（即4-5、2-3、0-1）的患者相比，合并症≥6的患者在30个月时的全因死亡率风险更高（59.5% vs. 38.6% vs. 17.0% vs. 7.9%, p = 0.001）。心血管共病（HR = 1.106; 95% CI 1.030 - 1.188; p = 0.006）和非心血管共病（HR = 1.564; 95% CI 1.470 - 1.664; p = 0.001）预测了长期全因死亡的风险。结论：在HFmrEF住院患者中，超过50%的患者至少有4种合并症。心血管和非心血管合并症均可预测HFmrEF患者的长期全因死亡风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Research in Cardiology 医学-心血管系统

CiteScore

11.40

自引率

4.00%

发文量

140

审稿时长

4-8 weeks

期刊介绍： Clinical Research in Cardiology is an international journal for clinical cardiovascular research. It provides a forum for original and review articles as well as critical perspective articles. Articles are only accepted if they meet stringent scientific standards and have undergone peer review. The journal regularly receives articles from the field of clinical cardiology, angiology, as well as heart and vascular surgery. As the official journal of the German Cardiac Society, it gives a current and competent survey on the diagnosis and therapy of heart and vascular diseases.